Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Muggia

Showing results (61-70 of 95) with videos related to

Pageof 10
Sort By:
Breast Cancer Research and Treatment|September 5, 2013
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literatureEleonora Teplinsky, Derrick Cheung, Ilan Weisberg, et al.
Gynecologic Oncology|October 29, 2005
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG studyHoward S Hochster, Elizabeth R Plimack, John Mandeli, et al.
The Breast Journal|April 1, 2015
Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical courseMaxwell Janosky, Jessica Bian, Shubhada Dhage, et al.
Gynecologic Oncology|January 15, 2008
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I studyHoward Hochster, Thomas T Chen, Janice M Lu, et al.
Seminars in Oncology|January 10, 2006
Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II studyElliot Newman, Milan Potmesil, Theresa Ryan, et al.
Anticancer Research|October 15, 2010
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancerTamar Safra, Eleni Andreopoulou, Benjamin Levinson, et al.
Clinical Breast Cancer|October 9, 2007
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancerEleni Andreopoulou, Darci Gaiotti, Eugene Kim, et al.
The Oncologist|May 25, 2012
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?Timothy L Cannon, Dominic W Lai, David Hirsch, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
The American Journal of Pathology|May 25, 2016
Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen EpitopeJennifer M Caron, Jacquelyn J Ames, Liangru Contois, et al.
Pageof 10

Showing results (61-70 of 95) with videos related to

Sort By:
Pageof 10
Breast Cancer Research and Treatment|September 5, 2013
Fatal hepatitis B reactivation due to everolimus in metastatic breast cancer: case report and review of literatureEleonora Teplinsky, Derrick Cheung, Ilan Weisberg, et al.
Gynecologic Oncology|October 29, 2005
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG studyHoward S Hochster, Elizabeth R Plimack, John Mandeli, et al.
The Breast Journal|April 1, 2015
Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical courseMaxwell Janosky, Jessica Bian, Shubhada Dhage, et al.
Gynecologic Oncology|January 15, 2008
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I studyHoward Hochster, Thomas T Chen, Janice M Lu, et al.
Seminars in Oncology|January 10, 2006
Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II studyElliot Newman, Milan Potmesil, Theresa Ryan, et al.
Anticancer Research|October 15, 2010
Weekly paclitaxel with intermittent imatinib mesylate (Gleevec): tolerance and activity in recurrent epithelial ovarian cancerTamar Safra, Eleni Andreopoulou, Benjamin Levinson, et al.
Clinical Breast Cancer|October 9, 2007
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancerEleni Andreopoulou, Darci Gaiotti, Eugene Kim, et al.
The Oncologist|May 25, 2012
Squamous cell carcinoma of the oral cavity in nonsmoking women: a new and unusual complication of chemotherapy for recurrent ovarian cancer?Timothy L Cannon, Dominic W Lai, David Hirsch, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
The American Journal of Pathology|May 25, 2016
Inhibition of Ovarian Tumor Growth by Targeting the HU177 Cryptic Collagen EpitopeJennifer M Caron, Jacquelyn J Ames, Liangru Contois, et al.
Pageof 10